CD82 and ovarian cancer: To investigate the impact of glycosylated CD82 on the peritoneal dissemination of ovarian cancer, ES2 cells were injected intraperitoneally for 4 mice per group (N=4) and analyzed for tumor growth four weeks post-injection (Figure 5F).